

**Laguna Honda Hospital  
URINE ISOLATES**

**JANUARY THROUGH DECEMBER 2019**

**PERCENT OF ISOLATES SUSCEPTIBLE TO ANTIMICROBIAL\***

| Enteric Urine Isolates | # Tested | AMP | PIPTZ | CZOL            | CTAZ | CTRX | CFPM | GENT | TOB | TMSX | CIPR | LEVO | NITRO | ETP |
|------------------------|----------|-----|-------|-----------------|------|------|------|------|-----|------|------|------|-------|-----|
| Klebsiella aerogenes   | 2        | R   | 100   | R               | 50   | 50   | 100  | 100  | 100 | 100  | 100  | 100  | 0     | 100 |
| Enterobacter cloacae   | 5        | R   | 100   | R               | 40   | 40   | 100  | 100  | 80  | 100  | 80   | 100  | 100   | 80  |
| Escherichia coli       | 101      | 56  | 96    | 76 <sup>^</sup> | 83   | 78   | 80   | 86   | 82  | 72   | 55   | 56   | 91    | 100 |
| ESBL                   | 27       |     | 85    |                 |      |      |      | 67   | 48  | 48   | 11   | 11   | 82    | 100 |
| Non ESBL               | 82       | 72  | 100   | 96 <sup>^</sup> | 99   | 99   | 100  | 93   | 93  | 79   | 68   | 70   | 95    | 100 |
| Klebsiella oxytoca     | 3        | 0   | 67    | 33              | 67   | 67   | 67   | 100  | 100 | 100  | 100  | 100  | 100   | 67  |
| Klebsiella pneumoniae  | 37       | R   | 97    | 97 <sup>^</sup> | 97   | 97   | 95   | 97   | 97  | 92   | 95   | 97   | 54    | 97  |
| Morganella morganii    | 3        | R   | 100   | R               | 67   | 67   | 100  | 0    | 33  | 33   | 0    | 33   | R     | 100 |
| Proteus mirabilis      | 52       | 75  | 100   | 92 <sup>^</sup> | 94   | 96   | 92   | 79   | 85  | 69   | 60   | 73   | R     | 100 |
| Providencia stuartii   | 3        | R   | 100   | R               | 100  | 100  | 100  | R    | R   | 100  | 100  | 100  | R     | 67  |

| Non-Enteric Urine Isolates | # Tested | PIPTZ | CTAZ | CFPM | GENT | TOB | CIPR | LEVO | MERO |
|----------------------------|----------|-------|------|------|------|-----|------|------|------|
| Pseudomonas aeruginosa     | 16       | 81    | 88   | 88   | 81   | 100 | 81   | 69   | 75   |

| Gram Positive Urine Isolates | # Tested  | AMP             | AMCL | DICLOX | CZOL | CTRX | TMSX | LEVO |
|------------------------------|---|-----------------|------|--------|------|------|------|------|
| Staphylococcus aureus        | 12  | 25 <sup>#</sup> | 50   | 50     | 50   | 50   | 100  | 25   |
| Staphylococcus saprophyticus | Uncomplicated UTIs respond to achievable urine levels of 1st generation Cephalosporins, Nitrofurantoin, Trimeth/Sulfa, or Fluoroquinolones. |                 |      |        |      |      |      |      |

\* First isolate per patient for the organism. Statistical validity of % susceptible is decreased if fewer than 30 isolates are tested.

<sup>^</sup> Percent susceptible if UTI is uncomplicated

<sup>#</sup> Percent susceptible determined by MIC and rapid beta-lactamase test

**Laguna Honda Hospital  
AEROBIC ISOLATES NON-URINE SOURCES  
JANUARY THROUGH DECEMBER 2019**

**PERCENT OF ISOLATES SUSCEPTIBLE TO ANTIMICROBIAL\***

| Enteric Isolates      | # Tested | AMP | PIPTZ | CZOL | CTAZ | CTRX | CFPM | GENT | TOB | TMSX | CIPR | LEVO | ETP |
|-----------------------|----------|-----|-------|------|------|------|------|------|-----|------|------|------|-----|
| Klebsiella aerogenes  | 3        | R   | 100   | R    | 100  | 100  | 100  | 100  | 100 | 100  | 67   | 67   | 100 |
| Escherichia coli      | 14       | 50  | 100   | 57   | 64   | 64   | 64   | 71   | 64  | 64   | 43   | 43   | 100 |
| Klebsiella pneumoniae | 4        | R   | 100   | 100  | 100  | 100  | 100  | 100  | 100 | 100  | 75   | 75   | 100 |
| Proteus mirabilis     | 17       | 71  | 100   | 77   | 100  | 94   | 100  | 77   | 82  | 65   | 41   | 47   | 100 |

| Non Enteric Isolates   | # Tested | PIPTZ | CTAZ | CFPM | GENT | TOB | CIPR | LEVO | MERO |
|------------------------|----------|-------|------|------|------|-----|------|------|------|
| Pseudomonas aeruginosa | 11       | 91    | 100  | 91   | 91   | 91  | 91   | 91   | 82   |

| Gram Positive Isolates             | # Tested  | PCN             | AMP             | AMCL | DICLOX | CZOL | CTRX | ERYT | CLIN^ | TET | VAN | TMSX | LEVO |
|------------------------------------|---|-----------------|-----------------|------|--------|------|------|------|-------|-----|-----|------|------|
| Staphylococcus aureus              | 13  | 31 <sup>#</sup> | 31 <sup>#</sup> | 69   | 69     | 69   | 69   | 62   | 77    | 85  | 100 | 92   | 54   |
| Methicillin Resistant              | 4   | 0               | 0               | 0    | 0      | 0    | 0    | 50   | 75    | 50  | 100 | 75   | 0    |
| Methicillin Susceptible            | 10  | 50 <sup>#</sup> | 50 <sup>#</sup> | 100  | 100    | 100  | 100  | 70   | 80    | 100 | 100 | 100  | 80   |
| Staphylococcus, coagulase-negative | 8   | 63              | 63              | 88   | 75     | 75   | 75   | 75   | 88    | 88  | 100 | 88   | 88   |
|                                    | Staphylococci resistant to Dicloxacillin are resistant to PCN, AMP, AMCL, TICL, PIPTZ, Cephems (CZOL, CTAZ, CTRX, CFPM), & Carbapenems. |                 |                 |      |        |      |      |      |       |     |     |      |      |

\* First isolate per patient for the organism. Statistical validity of % susceptible is decreased if fewer than 30 isolates are tested.

^ Clindamycin results determined by two tests (MIC and inducible Clindamycin resistance test)

# Percent susceptible determined by MIC and rapid beta-lactamase test. Additional penicillin zone edge test performed on sterile sites only.